Page 57 - TD-3-4

Tumor Discovery PPAR agonist and cancer

Mol Cancer Ther. 2008;7(7):1871-1879. the progression of preinvasive lung cancer in a murine
model. Carcinogenesis. 2009;30(12):2095-2099.
doi: 10.1158/1535-7163.MCT-08-0308
doi: 10.1093/carcin/bgp260
69. Miao R, Xu T, Liu L, et al. Rosiglitazone and retinoic
acid inhibit proliferation and induce apoptosis in the 79. Annicotte JS, Iankova I, Miard S, et al. Peroxisome
HCT-15 human colorectal cancer cell line. Exp Ther Med. proliferator-activated receptor gamma regulates E-cadherin
2011;2(3):413-417. expression and inhibits growth and invasion of prostate
cancer. Mol Cell Biol. 2006;26(20):7561-7574.
doi: 10.3892/etm.2011.227
doi: 10.1128/MCB.00605-06
70. Cao LQ, Wang XL, Wang Q, et al. Rosiglitazone sensitizes
hepatocellular carcinoma cell lines to 5-fluorouracil antitumor 80. Huang G, Yin L, Lan J, et al. Synergy between peroxisome
activity through activation of the PPARgamma signaling proliferator-activated receptor γ agonist and radiotherapy in
pathway. Acta Pharmacol Sin. 2009;30(9):1316-1322. cancer. Cancer Sci. 2018;109(7):2243-2255.
doi: 10.1038/aps.2009.119 doi: 10.1111/cas.13650
71. Saidi SA, Holland CM, Charnock-Jones DS, Smith SK. 81. Chen X, Duan N, Zhang C, Zhang W. Survivin and
In vitro and in vivo effects of the PPAR-alpha agonists tumorigenesis: Molecular mechanisms and therapeutic
fenofibrate and retinoic acid in endometrial cancer. Mol strategies. J Cancer. 2016;7(3):314.
Cancer. 2006;5:13. doi: 10.7150/jca.13332
doi: 10.1186/1476-4598-5-13 82. Bie Q, Dong H, Jin C, Zhang H, Zhang B. 15d-PGJ2 is a
72. Hamaguchi N, Hamada H, Miyoshi S, et al. In vitro and new hope for controlling tumor growth. Am J Transl Res.
in vivo therapeutic efficacy of the PPAR-γ agonist troglitazone 2018;10(3):648-658.
in combination with cisplatin against malignant pleural 83. Wang Y, Tan H, Xu D, et al. The combinatory effects of
mesothelioma cell growth. Cancer Sci. 2010;101(9):1955-1964. PPAR-γ agonist and survivin inhibition on the cancer stem-
doi: 10.1111/j.1349-7006.2010.01632.x like phenotype and cell proliferation in bladder cancer cells.
Int J Mol Med. 2014;34(1):262-268.
73. Copland JA, Marlow LA, Kurakata S, et al. Novel high-
affinity PPARgamma agonist alone and in combination doi: 10.3892/ijmm.2014.1774
with paclitaxel inhibits human anaplastic thyroid 84. Nogueira V, Hay N. Molecular pathways: Reactive oxygen
carcinoma tumor growth via p21WAF1/CIP1. Oncogene. species homeostasis in cancer cells and implications for
2006;25(16):2304-2317. cancer therapy. Clin Cancer Res. 2013;19(16):4309-4314.
doi: 10.1038/sj.onc.1209267 doi: 10.1158/1078-0432.CCR-12-1424
74. Alqahtani QH, Alkharashi LA, Alajami H, Alkharashi I, 85. Arfin S, Jha NK, Jha SK, et al. Oxidative stress in cancer cell
Alkharashi L, Alhinti SN. Pioglitazone enhances cisplatin’s metabolism. Antioxidants (Basel). 2021;10(5):642.
impact on triple-negative breast cancer: Role of PPAR-γ in
cell apoptosis. Saudi Pharm J. 2024;32(5):102059. doi: 10.3390/antiox10050642
doi: 10.1016/j.jsps.2024.102059 86. Knopfová L, Smarda J. The use of Cox-2 and PPAR-γ signaling
in anti-cancer therapies. Exp Ther Med. 2010;1(2):257-264.
75. Pouya FD, Salehi R, Rasmi Y, Kheradmand F, Fathi-
Azarbayjani A. Combination chemotherapy against doi: 10.3892/etm_00000040
colorectal cancer cells: Co-delivery of capecitabine 87. Han EJ, Im CN, Park SH, Moon EY, Hong SH. Combined
and pioglitazone hydrochloride by polycaprolactone- treatment with peroxisome proliferator-activated receptor
polyethylene glycol carriers. Life Sci. 2023;332:122083. (PPAR) gamma ligands and gamma radiation induces
apoptosis by PPAR-γ-independent up-regulation of reactive
doi: 10.1016/j.lfs.2023.122083
oxygen species-induced deoxyribonucleic acid damage
76. Novikov NM, Zolotaryova SY, Gautreau AM, Denisov EV. signals in non-small cell lung cancer cells. Int J Radiat Oncol
Mutational drivers of cancer cell migration and invasion. Br Biol Phys. 2013;85(5):e239-e248.
J Cancer. 2021;124(1):102-114.
doi: 10.1016/j.ijrobp.2012.11.040
doi: 10.1038/s41416-020-01149-0
88. Park BH, Lee SB, Stolz DB, Lee YJ, Lee BC. Synergistic
77. Wang Q, Peng H, Qi X, Wu M, Zhao X. Targeted therapies interactions between heregulin and peroxisome proliferator-
in gynecological cancers: A comprehensive review of clinical activated receptor-gamma (PPARgamma) agonist in breast
evidence. Signal Transduct Target Ther. 2020;5(1):137. cancer cells. J Biol Chem. 2011;286(22):20087-20099.
doi: 10.1038/s41392-020-0199-6 doi: 10.1074/jbc.M110.191718
78. Lyon CM, Klinge DM, Do KC, et al. Rosiglitazone prevents 89. Higuchi T, Sugisawa N, Miyake K, et al. Pioglitazone, an

Volume 3 Issue 4 (2024) 14 doi: 10.36922/td.4003